Larimar Therapeutics (LRMR) Expected to Announce Earnings on Thursday

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Larimar Therapeutics to post earnings of ($0.31) per share for the quarter.

Larimar Therapeutics Stock Performance

Shares of NASDAQ LRMR traded down $0.03 during mid-day trading on Friday, reaching $3.03. The company's stock had a trading volume of 284,414 shares, compared to its average volume of 543,212. The stock has a 50-day moving average of $3.44 and a two-hundred day moving average of $5.67. The stock has a market capitalization of $193.34 million, a P/E ratio of -2.63 and a beta of 0.99. Larimar Therapeutics has a 1-year low of $2.52 and a 1-year high of $11.49.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on LRMR. Truist Financial began coverage on shares of Larimar Therapeutics in a research report on Wednesday, January 29th. They issued a "buy" rating and a $18.00 target price for the company. HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Larimar Therapeutics in a research report on Friday, January 24th. Finally, William Blair reiterated an "outperform" rating on shares of Larimar Therapeutics in a research report on Tuesday, November 19th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Larimar Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $20.13.

Remove Ads

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.